Market News & Trends
STADA & Alvotech Secure Approval for Europe’s First Ustekinumab Biosimilar to Stelara
Partners STADA and Alvotech recently announced the European Commission issued a marketing authorization for Uzpruvo (AVT04), a biosimilar candidate to Stelara (ustekinumab). The centralized marketing….
Revive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of Bucillamine
Revive Therapeutics Ltd. recently announced it has completed the formulation development work of its next-generation lyophilized formulation of Bucillamine (New Bucillamine) conducted at the University…
Verge Genomics Announces Initiation of Proof-of-Concept Study for the Treatment of Amyotrophic ALS
Verge Genomics recently announced the initiation of its Phase 1b proof-of-concept study of VRG50635 for the treatment of sporadic and familial forms of amyotrophic lateral…
Lexaria Bioscience Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug Delivery Platform
Lexaria Bioscience Corp. recently announced its placement in an editorial published by NetworkNewsWire (NNW), one of 60+ brands within the….
Nanoform Commenced Relative Bioavailability Study of Nanotechnology-Enhanced Enzalutamide
Nanoform Finland Plc recently announced it had completed the First Subject First Visit (FSFV) in a trial to evaluate the relative bioavailability of its nanocrystalline…
Enzene Biosciences Launches its First Manufacturing Base in the US, With Additional Plans to Establish Continuous Manufacturing Operations at its New Jersey Site
Widely recognized as a pioneer in continuous manufacturing, Pune-based Contract Development & Manufacturing Organization (CDMO), Enzene Biosciences has announced the launch of its first manufacturing site in the US, located in….
Biora Therapeutics Announces Initiation of Phase 1 Clinical Study for Drug-Device combination Program
Biora Therapeutics, Inc. recently announced initiation of its Phase 1, first-in-human clinical study of BT-600 in healthy adult volunteers. BT-600 is a drug-device combination program consisting of the orally….
Olema Oncology Nominates Orally Bioavailable KAT6 Inhibitor as a Development Candidate
Olema Pharmaceuticals, Inc. recently announced the selection of a development candidate for the its program targeting KAT6, an epigenetic target that is dysregulated in breast…
Artelo Biosciences Announces Selection of Worldwide Clinical Trials as CRO to Support First-in-Human Study
Artelo Biosciences, Inc. recently announced it has selected Worldwide Clinical Trials to support the its planned Phase 1 trial with ART26.12, its Fatty Acid Binding…
CordenPharma & pHLIP Announce Strategic Alliance to Develop pHLIP LNP Targeted Delivery Platform for RNA & Gene Therapies
CordenPharma International and pHLIP, Inc. recently announce their strategic alliance to collaborate in developing and commercializing the pHLIP-LNP targeted delivery platform for RNA-based and genetic…
Sitryx Announces Collaboration Partner Lilly Has Commenced Phase 1 Study of SIT-011 for Chronic Autoimmune & Inflammatory Diseases
Sitryx Therapeutics recently announced Eli Lilly & Company has commenced a Phase 1 first-in-human study of SIT-011, a post-translational modification modulator program for chronic autoimmune and….
Rhythm Pharmaceuticals & LG Chem Life Sciences Enter Agreement for Rhythm to Acquire Global Rights to Oral MC4R Agonist LB54640
Rhythm Pharmaceuticals, Inc. recently announced it has entered into a global licensing agreement with LG Chem, Ltd. for LB54640, an investigational oral small molecule melanocortin-4…
Boehringer Ingelheim Licenses Multiple Dark Antigens From Enara Bio to Develop Off-the-Shelf Immunotherapies for Non-Small Cell Lung Cancer
Enara Bio recently announced Boehringer Ingelheim has exercised its option to license a number of cancer antigens discovered and validated through the ongoing collaboration using…
Gerresheimer & Aptar Digital Health Collaborate to Develop Integrated Solution for Cancer Therapy
Gerresheimer and Aptar Digital Health recently announced they will collaborate to develop an integrated solution for cancer therapy management. As part of this collaboration….
Avenue Therapeutics Reaches Final Agreement with the FDA for Phase 3 Safety Study for IV Tramadol
Avenue Therapeutics, Inc. recently announced it has reached final agreement with the US FDA on the Phase 3 safety study protocol and statistical analysis approach,…
BriaCell Images Confirm Robust Anti-Tumor Activity in Patient with “Eye-Bulging” Metastatic Breast Cancer
BriaCell Therapeutics Corp. recently released transformational images of the recently reported remarkable responder in the Phase 2 study of BriaCell’s Bria-IMT combination regimen…..
Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD
Silo Pharma, Inc. recently provided an update on its previously announced dose-ranging study of SPC-15, a targeted prophylactic treatment for post-traumatic stress disorder (PTSD). The…
Elektrofi & Janssen Biotech Enter Worldwide Collaboration & License Agreement to Exclusively Develop Up to Five Programs Utilizing Elektrofi’s Formulation Technology
Elektrofi, Inc. recently announced it has entered a multi-target worldwide research collaboration and license agreement with Janssen Biotech, Inc. (Janssen), a Johnson & Johnson company. This collaboration will initially focus on developing an at home….
OBI Pharma Announces US FDA Clearance of IND Application for a Phase 1/2 Study of OBI-992
OBI Pharma recently announced the US FDA has cleared an investigational new drug (IND) application for OBI-992, to conduct a Phase 1/2 study of its…
Ampersand Biomedicines Acquires AbCheck to Accelerate Platform and Product Development
Acquisition amplifies Ampersand’s in-house capabilities to generate AND-Body Therapeutics – programmed biologics across a broad range of diseases….
